Investigational Drug Information for Cytisinicline
✉ Email this page to a colleague
What is the drug development status for Cytisinicline?
Cytisinicline is an investigational drug.
There have been 9 clinical trials for Cytisinicline.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 28th 2024.
The most common disease conditions in clinical trials are Smoking Cessation, Renal Insufficiency, and Tobacco Use Disorder. The leading clinical trial sponsors are Achieve Life Sciences, University of California, Los Angeles, and [disabled in preview].
There are three hundred and sixty-two US patents protecting this investigational drug and zero international patents.
Summary for Cytisinicline
| US Patents | 362 |
| International Patents | 2,012 |
| US Patent Applications | 958 |
| WIPO Patent Applications | 492 |
| Japanese Patent Applications | 114 |
| Clinical Trial Progress | Phase 1 (2024-05-28) |
| Vendors | 62 |
Recent Clinical Trials for Cytisinicline
| Title | Sponsor | Phase |
|---|---|---|
| Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | University of California, Los Angeles | PHASE2 |
| Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers | Achieve Life Sciences | PHASE3 |
| Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers | Achieve Life Sciences | Phase 1 |
Clinical Trial Summary for Cytisinicline
Top disease conditions for Cytisinicline
Top clinical trial sponsors for Cytisinicline
US Patents for Cytisinicline
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Cytisinicline | ⤷ Start Trial | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | ⤷ Start Trial |
| Cytisinicline | ⤷ Start Trial | Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases | International Stem Cell Corporation (Carlsbad, CA) | ⤷ Start Trial |
| Cytisinicline | ⤷ Start Trial | 1,4-disubstituted 1,2,3-triazoles, methods for preparing same, and diagnostic and therapeutic uses thereof | Centre National de la Recherche Scientifique CNRS , Institut National de la Sante et de la Recherche Medicale INSERM | ⤷ Start Trial |
| Cytisinicline | ⤷ Start Trial | Nicotinic attenuation of CNS inflammation and autoimmunity | Dignity Health (San Francisco, CA) | ⤷ Start Trial |
| Cytisinicline | ⤷ Start Trial | Dietary supplements and formulations | Eastern Vision Limited (Wanchai, HK) | ⤷ Start Trial |
| Cytisinicline | ⤷ Start Trial | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases | NEUROCEA, LLC (Los Altos, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Cytisinicline
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Cytisinicline | World Intellectual Property Organization (WIPO) | WO2014052836 | 2032-09-27 | ⤷ Start Trial |
| Cytisinicline | European Patent Office | EP2961277 | 2033-02-15 | ⤷ Start Trial |
| Cytisinicline | Hong Kong | HK1215358 | 2033-02-15 | ⤷ Start Trial |
| Cytisinicline | Japan | JP2016508520 | 2033-02-15 | ⤷ Start Trial |
| Cytisinicline | World Intellectual Property Organization (WIPO) | WO2014127289 | 2033-02-15 | ⤷ Start Trial |
| Cytisinicline | Australia | AU2012245118 | 2031-04-20 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
